Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: A meta analysis

Chinese Medical Journal

Volumn 126, Issue 9, 2013, Pages 1755-1760

  Li, Xiang Dong ^a   Yang, Yue Jin ^a   Hao, Yong Chen ^a   Yang, Ying ^a   Zhao, Jing Lin ^a   Dou, Ke Fei ^a   Gu, Dong Feng ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary artery disease; No reflow; Percutaneous Coronary Intervention; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; GENETIC HETEROGENEITY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; META ANALYSIS; MYOCARDIAL DISEASE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINES AS TOPIC;

EID: 84876888640     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122700     Document Type: Article

References (36)

1. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the "no reflow" phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-228.
2. Stone G.W, Peterson M.A, Lansky A.J, Dangas G, Mehran R, Leon M.B. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002; 39: 591-597.
3. Resnic F.S, Wainstein M, Lee M.K, Behrendt D, Wainstein R.V, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-46.
4. Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008; 29: 1843-1850.
5. Verma S, Fedak P.W, Weisel R.D, Butany J, Rao V, Maitland A, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105: 2332-2336.
6. Bekkers S.C, Yazdani S.K, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010; 55: 1649-1660.
7. Mood G.R, Bavry A.A, Roukoz H, Bhatt D.L. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007; 100: 919-923.
8. Baigent C, Keech A, Kearney P.M, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
9. Schwartz B.G, Kloner R.A. Coronary no reflow. J Mol Cell Cardiol 2011; 52: 873-882.
10. Oduncu V, Tanalp A.C, Erkol A, Sirma D, Dundar C, Akgun T, et al. Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol 2011; 107: 179-185.
11. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27: 534-539.
12. Gibson C.M, Morrow D.A, Murphy S.A, Palabrica T.M, Jennings L.K, Stone P.H, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006; 47: 2364-2373.
13. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004; 25: 1822-1828.
14. Moher D, Liberati A, Tetzlaff J, Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
15. Chyrchel M, Rakowski T, Rzeszutko L, Legutko J, Dziewierz A, Dubiel JS, et al. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol 2006; 64: 1357-1363.
16. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-2183.
17. Veselka J, Prochazkova S, Duchonova R, Homolova I, Tesar D, Bybee K.A. Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Heart Vessels 2006; 21: 146-151.
18. Celik T, Kursaklioglu H, Iyisoy A, Kose S, Kilic S, Amasyali B, et al. The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coron Artery Dis 2005; 16: 321-326.
19. De Luca G, Suryapranata H, Ottervanger J.P, van't Hof AW, Hoorntje J.C, Gosselink A.T, et al. Impact of statin therapy at discharge on 1-year mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. Atherosclerosis 2006; 189: 186-192.
20. Ishii H, Ichimiya S, Kanashiro M, Aoyama T, Ogawa Y, Murakami R, et al. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther 2006; 28: 1812-1819.
21. Zhao J.L, Yang Y.J, Pei W.D, Sun Y.H, Chen J.L. The effect of statins on the no-reflow phenomenon: an observational study in patients with hyperglycemia before primary angioplasty. Am J Cardiovasc Drugs 2009; 9: 81-89.
22. Kim J.S, Kim J, Choi D, Lee C.J, Lee S.H, Ko Y.G, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010; 3: 332-339.
23. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157-2163.
24. Hahn J.Y, Kim H.J, Choi Y.J, Jo S.H, Kim H.J, Lee S, et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2011; 162: 1026-1033.
25. Jia X.W, Fu X.H, Zhang J, Gu X.S, Fan W.Z, Wu W.L, et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J 2009; 122: 659-664.
26. Yun K.H, Jeong M.H, Oh S.K, Rhee S.J, Park E.M, Lee E.M, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009; 137: 246-251.
27. Lev E.I, Kornowski R, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, et al. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2009; 103: 165-169.
28. Jaffe R, Charron T, Puley G, Dick A, Strauss B.H. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008; 117: 3152-3156.
29. Yang Y.J, Qian H.Y, Huang J, Li J.J, Gao R.L, Dou K.F, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol 2009; 29: 2076-2082.
30. Yang Y.J, Qian H.Y, Huang J, Geng Y.J, Gao R.L, Dou K.F, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008; 29: 1578-1590.
31. Merla R, Ye Y, Lin Y, Manickavasagam S, Huang M.H, Perez-Polo R.J, et al. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol 2007; 293: H1918-H1928.
32. Zhao J.L, Yang Y.J, Cui C.J, You S.J, Gao R.L. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol 2006; 149: 243-249.
33. Efthymiou C.A, Mocanu M.M, Yellon D.M. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 2005; 45: 247-252.
34. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009; 120: 1822-1836.
35. Hamm C.W, Bassand J.P, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
36. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.